Compass Pathways Akcia

Compass Pathways AAQS

AAQS spoločnosti Compass Pathways (CMPS) k 15. 8. 2026 je 4. V predchádzajúcom roku AAQS bolo 4,00 — zmena o 0,00 % (nižšie).

AAQS

4

YoY

0,00%

Naposledy aktualizované:

Compass Pathways má aktuálny AAQS 4. Vysoký AAQS môže byť považovaný za pozitívny ukazovateľ, že spoločnosť sa vyvíja úspešne. Investori môžu očakávať, že spoločnosť je na dobrej ceste dosahovať zisky. Na druhej strane je dôležité porovnať AAQS akcie Compass Pathways vzhľadom na dosiahnuté zisky a ostatné spoločnosti v tej istej odvetví. Vysoký AAQS nie je absolútnou zárukou pozitívnej budúcnosti. Len takto môžeme získať úplný obraz o výkonnosti spoločnosti. Aby sme lepšie mohli posúdiť vývoj spoločnosti, je dôležité porovnávať AAQS s inými spoločnosťami v rovnakej odvetví. Všeobecne by investori mali vždy hodnotiť AAQS spoločnosti v súvislosti s inými finančnými ukazovateľmi ako zisk, EBIT, Cash Flow a ďalšími, aby mohli urobiť informované investičné rozhodnutie.
Access this data via the Eulerpool API

Compass Pathways Analýza akcií

Čo robí Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways je jednou z najobľúbenejších spoločností na Eulerpool.

Často kladené otázky o akcii Compass Pathways

AAQS spoločnosti Compass Pathways je 4 v roku 2026.

Na Eulerpool nájdete kompletnú historickú evolúciu Compass Pathways AAQS od roku 2006 – s ročnými hodnotami, grafmi a detailnou analýzou.

AAQS je ukazovateľ vyvinutý spoločnosťou AlleAktien.

AAQS je ukazovateľ vyvinutý spoločnosťou AlleAktien.

Access this data via the Eulerpool API

Kvalita — Compass Pathways

Všetky kľúčové ukazovatele — Compass Pathways